Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from LifeTech Scientific Corporation ( (HK:1302) ).
LifeTech Scientific Corporation announced its interim results for the six months ending June 30, 2025, reporting a turnover of approximately RMB676.7 million, a 3.7% increase from the previous year. However, the company’s net profit, after accounting for non-recurring items, saw a significant decrease of 73.2% compared to the same period in 2024, primarily due to changes in financial asset gains and increased share-based payment expenses.
The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation is a company incorporated in the Cayman Islands, operating in the medical technology industry. It focuses on developing and providing medical devices and solutions, particularly in the area of cardiovascular and peripheral vascular diseases.
Average Trading Volume: 43,927,223
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.85B
Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.